Conclusions
migraine
MIGRAINE
Once-monthly galcanezumab 120 mg was efficacious and well-tolerated for up to 6 months in patients from China, India, and Russia with episodic migraine. Our results support the long-term findings from OLEs of prior pivotal phase 3 studies of galcanezumab in patients with migraine [